Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $64.9 million.

  • Spyre Therapeutics' Cash & Equivalents fell 933.64% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year decrease of 933.64%. This contributed to the annual value of $89.4 million for FY2024, which is 5265.94% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Cash & Equivalents is $64.9 million, which was down 933.64% from $81.7 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Cash & Equivalents peaked at $235.4 million during Q2 2023, and registered a low of $14.6 million during Q1 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $48.5 million (2025), whereas its average is $76.8 million.
  • In the last 5 years, Spyre Therapeutics' Cash & Equivalents tumbled by 8319.33% in 2021 and then soared by 54566.58% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Cash & Equivalents stood at $15.1 million in 2021, then skyrocketed by 130.24% to $34.9 million in 2022, then surged by 441.82% to $188.9 million in 2023, then crashed by 52.66% to $89.4 million in 2024, then decreased by 27.43% to $64.9 million in 2025.
  • Its Cash & Equivalents stands at $64.9 million for Q3 2025, versus $81.7 million for Q2 2025 and $48.5 million for Q1 2025.